Acquired resistance to PD-L1 inhibition is associated with an enhanced type I IFN-stimulated secretory program in tumor cells
Yuhao Shi(Roswell Park Comprehensive Cancer Center), John M.L. Ebos(Roswell Park Comprehensive Cancer Center)
Cited by 1
Related Papers
Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance
|PLoS ONE|2019|29
Machine-learning and mechanistic modeling of metastatic breast cancer after neoadjuvant treatment
|PLoS Computational Biology|2024|19